Class in: Science and Technology, Sant
Subjects: Conference, Product/Service, Webcast, Annual Meeting
Incyte (Nasdaq: INCY) today announced that multiple abstracts containing data from its dermatology portfolio will be presented at the upcoming American Academy of Dermatology (AAD) Annual Meeting in San Diego, March 8-12, 2024.
“We are pleased to attend this year's AAD Annual Meeting and share data, including two recent presentations drawn from our growing dermatology portfolio,” said Jim Lee, MD, Ph.D., Vice President of the Inflammation and Autoimmunity Group . at Incyte. Our presence at this year's meeting demonstrates Incyte's commitment to finding solutions for patients whose urgent needs remain unmet. We are pleased to share clinical data evaluating ruxolitinib cream and povorcitinib in immune-mediated dermatologic diseases, including atopic dermatitis, vitiligo, hidradnitis suppurativa, and prurigo nodularis.
Main summaries:
Last minute lectures
Nodular prurigo
Efficacy and safety of povorcitinib in patients with prurigo nodularis: results of a randomized, double-blind, placebo-controlled phase 2 study (Session: S050 – Current Research: Session 2. Sunday, March 10, 2024, 4:00 p.m. Eastern Time)
Hidradnitis suppurate
Efficacy and safety of ruxolitinib cream in patients with hidradnitis suppurativa (Hurley stages I and II): results of a randomized, double-blind, vehicle-controlled phase 2 study (Session: S050 – Current Research: Session 2. Sunday, March 10, 2024, 4:10 p.m. Eastern Time)
Electronic poster presentation accompanied by a short oral presentation
Atopic dermatitis
Efficacy of ruxolitinib cream for the treatment of atopic dermatitis in children aged 2 <12 years based on medication history: subgroup analysis from the randomized phase 3 TRuE-AD3 trial (Abstract #54214. Friday, March 8, 2024, 4:10 p.m. – 4:15 p.m. Eastern Time. Upper Floor, Sail Pavilion, Poster Center 2)
Electronic poster presentations
Atopic dermatitis
Effects of Ruxolitinib Cream on Patient-Reported Outcomes (PRO) in Children Age 2 <12 Years With Atopic Dermatitis (AD): Results from a Phase 3 Randomized Trial, Double-Blind, Vehicle-Controlled (TruE-AD3) (Abstract #49439)
Atopic dermatitis (AD) treatments before and after introduction of ruxolitinib cream: analysis of a US claims database (Abstract #53102)
Real-world clinical experience with ruxolitinib cream as monotherapy for the treatment of atopic dermatitis (Abstract #53107)
Trial of Maximum Use of Ruxolitinib Cream in Children 2 < 12 Years of Age With Atopic Dermatitis (AD): Patient Reported Outcomes (PRO) at Week 8 (Abstract #54025)
Efficacy of Ruxolitinib Cream for the Treatment of Atopic Dermatitis in Children 2 <12 Years of Age Based on Baseline Clinical Characteristics: Subgroup Analysis of a Randomized Phase 3 Trial (TRuE-AD3) (Abstract #54147)
Trials of maximum use of ruxolitinib cream in adults, adolescents and children aged 2 to 12 years with atopic dermatitis: consistency of safety, pharmacokinetics and efficacy (Abstract #54168)
Vitiligo
Serum protein biomarkers may provide evidence of early immune activity after discontinuation of ruxolitinib cream in the TRuE-V long-term extension study Summary #50342)
Efficacy of povorcitinib in the treatment of vitiligo based on baseline patient demographics and clinical characteristics: subgroup analysis at week 52 of a randomized, placebo-controlled phase 2b clinical trial (Abstract #53962)
Relationship between the Vitiligo Severity Index (Vitiligo Area Scoring Index) and the Vitiligo Extent Score? Plus: Responses from a Phase 2b, randomized, double-blind, placebo-controlled, dose-ranging study (Abstract #53971)
All summaries will be available on the online triage portal and on site at the triage stations. They will also be published online in the Fall 2024 supplement of the Journal of the American Academy of Dermatology (JAAD).
For more information about the 2024 AAD Annual Meeting, visit https://www.aad.org/member/meetings-education/am24.
Conference call and webcast
Incyte will host an in-person event for analysts and investors to discuss key “AAD” data presentations on Monday, March 11, 2024, from 9:00 a.m. to 10:30 a.m. PT (12:00 p.m. to 1:30 p.m. Eastern Time). . The event will be webcast and will be accessible via the Events & Presentations tab in the Investors section of Incyte.com. It can be collected for 30 days.
Details of the conference call will be posted on our website.
About Opzelura (ruxolitinib) Cream 1.5%
Opzelura, a new cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, has been approved by the U.S. Food & Drug Administration for the topical treatment of non-segmental vitiligo in patients 12 years of age and older, becoming the first and only in the United States approved treatment for repigmentation. Opzelura is also approved in the United States for the short-term topical treatment and discontinuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled. on prescription topical treatments or when these treatments are not recommended. The use of Opzelura in combination with therapeutic biologics, other JAK inhibitors or strong immunosuppressants such as azathioprine or ciclosporin is not recommended.
In Europe, Opzelura (ruxolitinib) cream 15 mg/g is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents aged 12 years and older.
Incyte has worldwide rights to develop and commercialize ruxolitinib cream, which is marketed in the United States under the name Opzelura.
Opzelura and the Opzelura logo are registered trademarks of Incyte.
About Povorcitinib (INCB54707)
Povorcitinib (INCB54707) is an oral, small molecule JAK1 inhibitor currently in Phase 2 clinical trials for vitiligo, hidradnitis suppurativa (HS), and prurigo nodularis. Phase 3 trials of HS are also underway.
About Incyte Dermatology
Incyte's predominantly scientific approach and expertise in immunology form the foundation of the company. Today, we draw on this heritage to discover and develop innovative dermatological treatments to provide solutions to patients who need them.
In dermatology, our research and development efforts are primarily focused on leveraging our knowledge of the JAK-STAT signaling pathway. We are exploring the potential of JAK inhibition for a number of immune-mediated dermatological diseases that continue to have significant unmet medical needs, including atopic dermatitis, vitiligo, hidradenitis suppurativa, lichen planus, lichen sclerosus and prurigo nodularis.
For more information, visit the Dermatology section of Incyte.com.
About Incyte
As a global biopharmaceutical company with a mission to continue solving problems (Solve On.), Incyte follows science to find solutions for patients whose medical needs are unmet. Through the discovery, development and commercialization of proprietary therapeutic products, Incyte has built a portfolio of best-in-class patient medicines and a robust product portfolio in oncology, inflammation and autoimmunity. Incyte is headquartered in Wilmington, Delaware, and has offices in North America, Europe and Asia. For more information about Incyte, visit Incyte.com or follow us on social media: LinkedIn, XInstagram, Facebook, YouTube.
forward-looking statements
Except for the historical information contained herein, the information contained in this press release, including statements regarding the presentation of data from Incyte's clinical development pipeline, applies to whether or when compounds or combinations in development will be approved for use in humans anywhere in the world or will be commercially available for indications already approved in certain regions and Incyte's mission to improve patients' lives contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on Incyte's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including unanticipated developments and various risk factors such as the following: unanticipated delays; the possibility that continued research and development and clinical trial results will be unsuccessful or insufficient to meet applicable regulatory standards or justify further development; the ability to enroll sufficient numbers of subjects in clinical trials; decisions of the U.S. FDA, AME and other regulatory authorities; the effectiveness or safety of Incyte and its partners' products; market acceptance of Incyte and its partners' products; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in Incyte's reports filed with the Securities and Exchange Commission, including its annual report and quarterly report on Form 10-Q for the quarter ended December 31, 2023. Incyte disclaims any intention or obligation to update these statements.
The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the Communiqué is the Communiqué in its original language. The translation must always be compared with the source text, which establishes the case law.
These press releases might also interest you
|
Press release sent on March 4, 2024 2:40 p.m. and distributed by:
